Navigation Links
Shareholder Class Action Filed Against LCA-Vision, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
Date:10/1/2007

RADNOR, Pa., Oct. 1 /PRNewswire-FirstCall/ -- The following statement was issued today by the law firm of Schiffrin Barroway Topaz & Kessler, LLP:

Notice is hereby given that a class action lawsuit was filed in the United States District Court for the Southern District of Ohio on behalf of all purchasers of securities of LCA-Vision, Inc. (Nasdaq: LCAV) ("LCA" or the "Company") from February 12, 2007 through July 30, 2007, inclusive (the "Class Period").

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Schiffrin Barroway Topaz & Kessler, LLP (Darren J. Check, Esq. or Richard A. Maniskas, Esq.) toll free at 1-888-299-7706 or 1-610-667-7706, or via e-mail at info@sbtklaw.com.

The Complaint charges LCA and certain of its officers and directors with violations of the Securities Exchange Act of 1934. LCA is engaged in the provision of fixed-site laser vision correction services at its LasikPlus vision centers. More specifically, the Complaint alleges that the Company failed to disclose and misrepresented the following material adverse facts which were known to defendants or recklessly disregarded by them: (1) that procedure volume at existing stores had significantly declined; (2) that overall growth was solely coming from new store openings; (3) that the Company was operating under defective assumptions about its marketing budget and deferred revenue; (4) that the Company lacked adequate internal and financial controls; and (5) that, as a result of the foregoing, the Company's statements about its financial well-being and future business prospects were lacking in a reasonable basis when made.

On July 31, 2007 the Company shocked investors when it reported abysmal second quarter 2007 financial and operational results, which included a decline in same-store procedure volume and a substantial rise in patient acquisition costs. Additionally, the Company reported lowering operating income, net income, and earnings per share ("EPS") than in the comparable 2006 quarter. As a result, the Company significantly lowered its EPS guidance from between $2.05 to $2.15 for full-year 2007 down to between $1.90 to $2.00 for full-year 2007.

On this news, the Company's shares declined $7.48 per share, or 17.4 percent, to close on July 31, 2007 at $35.51 per share, on unusually heavy trading volume. The following day, the Company's shares declined an additional $2.11 per share, or almost 6 percent, to close on August 1, 2007 at $33.40 per share, again on heavy trading volume.

Plaintiff seeks to recover damages on behalf of class members and is represented by the law firm of Schiffrin Barroway Topaz & Kessler which prosecutes class actions in both state and federal courts throughout the country. Schiffrin Barroway Topaz & Kessler is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world.

For more information about Schiffrin Barroway Topaz & Kessler or to sign up to participate in this action online, please visit http://www.sbtklaw.com

If you are a member of the class described above, you may, not later than November 13, 2007, move the Court to serve as lead plaintiff of the class, if you so choose. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as "lead plaintiff." Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Schiffrin Barroway Topaz & Kessler or other counsel of your choice, to serve as your counsel in this action.

CONTACT: Schiffrin Barroway Topaz & Kessler, LLP

Darren J. Check, Esq.

Richard A. Maniskas, Esq.

280 King of Prussia Road

Radnor, PA 19087

1-888-299-7706 (toll free) or 1-610-667-7706

Or by e-mail at info@sbtklaw.com


'/>"/>
SOURCE Schiffrin Barroway Topaz & Kessler, LLP
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Doyle repeals shareholder liability
2. Why repealing the shareholder wage lien law makes sense
3. Merge president steps down in wake of shareholder suits
4. Pressure mounts for Doyle to repeal shareholder liability law
5. Merges merger is the crux of shareholder lawsuits
6. RNase Activity in Mouse Tissue: Classification, Hierarchy, and Methods for Control
7. Screening and classifying hazardous waste samples
8. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
9. Early Stage, Step 8: Misclassifying workers brings risk
10. Healthcare software addresses "90 million" misclassified Americans
11. Classroom projects translate into immediate workplace gains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , January 20, 2017 ... is one of leading causes of death worldwide. There ... the number of cancer related deaths increased gradually over ... in incidence rate of various cancers continues to drive ... research report by Global Market Insights, Inc. cancer biological ...
(Date:1/19/2017)... Jan. 19, 2017 /PRNewswire -- WuXi AppTec, a ... capability and technology platform, today announced that it ... focused preclinical drug discovery contract research organization (CRO). ... a wholly-owned subsidiary of WuXi, and will continue ... providing greater services. The acquisition will further strengthen ...
(Date:1/19/2017)... CALABASAS, Calif. , Jan. 19, 2017 /PRNewswire/ ... Mathias Schmidt , Ph.D., as chief executive ... board of directors. Dr. Schmidt brings to ArmaGen more ... on the research and development of biotherapeutics and ... biopharmaceutical executive with the diverse experience and skillset ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... organization with services spanning the full spectrum of drug and device development, and ... services to pharma/device companies and clinicians, today announced Verified Clinical Trials ...
Breaking Biology Technology:
(Date:12/15/2016)... Dec. 15, 2016   WaferGen Bio-systems, Inc. ... technology company, announced today that on December 13, 2016, ... of The Nasdaq Stock Market LLC which acknowledged that, ... of WaferGen,s common stock had been at $1.00 or ... regained compliance with Listing Rule 5550(a)(2) of the Nasdaq ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the growth of ... expected to grow from USD 4.03 billion in 2015 ... of 29.3% between 2016 and 2022. The market is ... smart devices, government initiatives, and increasing penetration of e-commerce ... to grow at a high rate during the forecast ...
(Date:12/7/2016)... -- According to a new market research report "Emotion Detection and ... Recognition), Service, Application Area, End User, And Region - Global Forecast to 2021", ... Billion in 2016 to USD 36.07 Billion by 2021, at a Compound Annual ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):